India Supreme Court To Consider Adulterated-Drugs Suit Against Ranbaxy
This article was originally published in PharmAsia News
Executive Summary
India’s Supreme Court agreed to hear a public-interest lawsuit seeking cancellation of the license of Ranbaxy Laboratories to make drugs, but rejected a request for an interim production restraining order.